Insights
Search Results
News Articles
6.04.26
Wilson Sonsini Practices, Attorneys Recognized in 2026 Chambers USA Guide
The 2026 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 44 geography-specific practice categories and named 87 Wilson Sonsini attorneys among the best in their fields. This year, the firm received four new practice area rankings, including in the nationwide National Security and Capital Markets: Convertible Debt categories, and three improved practice area rankings.
News Articles
6.01.26
Wilson Sonsini Joins Nucleate Leadership Council as Co-Founding Member
On June 1, 2026, Nucleate, a nonprofit organization dedicated to empowering the next generation of biotech leaders, announced the launch of the Nucleate Leadership Council (NLC), a new community of biotech leaders and disruptors committed to supporting the next generation of scientists and entrepreneurs. Wilson Sonsini is proud to join the NLC as a co-founding member.
Client Highlights
1.27.26
Wilson Sonsini Advises Genyro on License Agreement with Caltech for “Sidewinder” Technology
On January 26, 2026, Genyro Inc., an early-stage, California-based biotechnology company advancing next-generation DNA construction, announced that it has entered into an exclusive licensing agreement with the California Institute of Technology (Caltech) for Sidewinder™, a breakthrough DNA construction invention recently featured in Nature. Wilson Sonsini Goodrich & Rosati advises Genyro on IP and corporate matters and represented the company in the licensing agreement with Caltech.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
Sidewinder represents the first DNA construction technology based on DNA 3-Way Junctions (3WJ), enabling the accurate construction of long, complex, and highly repetitive DNA sequences that have historically been challenging to build. The technology was developed by Professor Kaihang Wang, tenure-track assistant professor of biology and biological engineering at Caltech and co-founder and chief scientific advisor at Genyro. It is the first DNA construction method to separate the sequence information of the final assembled DNA product from the information guiding its assembly.
The Wilson Sonsini team advising Genyro includes Karen Deschaine, Lou Lieto, and Nellie Brutocao.
For more information, please see Genyro’s news release. Additional coverage of Genyro is available in The Times and Endpoints News.
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
Case Studies
12.11.25
How Wilson Sonsini Helped Ensure Light Horse Therapeutics’ Impressive Debut
Light Horse Therapeutics is pioneering new technologies to tackle the root causes of disabling and life-threatening diseases. Using precision gene editing applied to small-molecule drug discovery, its innovative approach is currently targeting historically challenging cancers, with plans to apply the technology to other therapeutic areas in the future.
Client Highlights
10.24.25
Wilson Sonsini Advises Elevara Medicines on IP Matters Related to $70 Million Series A Financing
On October 22, 2025, Elevara Medicines (Elevara), a clinical-stage biotech developing therapies for rheumatoid arthritis and chronic inflammatory diseases, announced the close of a $70 million Series A financing. The round was co-led by Forbion and Sofinnova Partners, with participation from founding investor Monograph Capital. Wilson Sonsini Goodrich & Rosati advised Elevara on IP matters related to the transaction.
Client Highlights
8.04.25
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering
On August 1, 2025, Prime Medicine, Inc., a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Wilson Sonsini Goodrich & Rosati advised Prime Medicine on IP matters related to the offering. The Wilson Sonsini team included Lou Lieto, Clark Lin, Rachna Ujwal, and Esther Cynn.
Client Highlights
6.17.25
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly
On June 17, 2025, Eli Lilly and Company and Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announced a definitive agreement for Lilly to acquire Verve. Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on IP matters related to the transaction.
News Articles
6.05.25
2025 Chambers USA Guide Recognizes Wilson Sonsini Practices, Attorneys
The 2025 Chambers USA guide has recognized Wilson Sonsini Goodrich & Rosati as a leading law firm in 39 geography-specific practice categories and named 86 Wilson Sonsini attorneys among the best in their fields. This year, the firm received three new practice area rankings, including in the Artificial Intelligence category, and four improved practice area rankings.